Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®

Inclusion Criteria:

• Are pre-menopausal women with or without child-bearing potential with a negative serumpregnancy test, and women with child-bearing potential receiving adequate birthcontrol

• Participants with diagnosis of clinically stable and definite relapsing multiplesclerosis (RMS)

• Adequate hematological, hepatic and renal function as defined in the protocol

• Are able and willing to accept dietary restrictions and restrictions regarding the useof concomitant medications (including over-the-counter products, herbal medicines anddietary supplements) over the course of the study

• Have a body weight and body mass index (BMI) within the range at screening

• Other protocol defined inclusion criteria could apply

Exclusion Criteria:

• History of clinically relevant allergy or known hypersensitivity to the activesubstance or to any of the excipients of cladribine tablets or hypersensitivity todrugs with a similar chemical structure to cladribine - History of clinically relevantallergy or known hypersensitivity to 1 of the active substances levonorgestrel (LNG)or ethinylestradiol (EE) or to any excipients of Microgynon® tablets

• Positive results from serology examination for Hepatitis B surface antigen (HbsAg) notdue to vaccination, hepatitis B core antibody (HbcAb), Hepatitis C virus antibody (anti- HCV) or Human Immunodeficiency antibody (anti-HIV)

• Presence or risk of venous thromboembolism (VTE) arterial thromboembolism (ATE)

• Diabetes mellitus (Type 1 or Type 2) with vascular manifestations

• Signs or symptoms of neurological disease other than multiple sclerosis (MS) thatcould explain the symptoms of the participant

• Presence of gastrointestinal (GI) disease or history of gastrointestinal -tractsurgery

• Exposure to another investigational drug within the last 2 months or within last 6month if agent is known to be immunosuppressive

• Other protocol defined exclusion criteria could apply